Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: Preclinical evaluation

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4240-4246

  Wahl, Ulrich ^a   Nößner, Elfriede ^a   Kronenberger, Konrad ^f   Gangnus, Rainer ^b   Pohla, Heike ^a,c   Staege, Martin S ^f   Kolb, Hans Jochem ^a,d   Hallek, Michael ^e   Mocikat, Ralph ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Urologische Klinik   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Gentherapie   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B CELL LEUKEMIA; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TRIOMA CELL; VACCINATION;

ADULT; AGED; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CHROMOSOME MAPPING; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MICE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0141455122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lanzavecchia, A. Antigen-specific interaction between T and B cells. Nature (Lond.), 314: 537-539, 1985.
2. Weiss, S., and Bogen, B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA, 86: 282-286, 1989.
3. Schultze, J. L., Cardoso, A. A., Freeman, G. J., Seamon, M. J., Daley, J., Pinkus, G. S., Gribben, J. G., and Nadler, L. M. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA, 92: 8200-8204, 1995.
4. Ronchese, F., and Hausmann, B. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J. Exp. Med., 177: 679-690, 1993.
5. Mocikat, R., Selmayr, M., Thierfelder, S., and Lindhofer, H. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res., 57: 2346-2349, 1997.
6. Snider, D. P., and Segal, D. M. Efficiency of antigen presentation following antigen targeting to surface IgD, IgM, MHC, FcγRII and B220 molecules on murine splenic B cells. J. Immunol., 143: 59-65, 1989.
7. Snider, D. P., Kaubisch, A., and Segal, D. M. Enhanced antigen immunogenicity induced by bispecific antibodies. J. Exp. Med., 171: 1957-1963, 1990.
8. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
9. Serre, K., Machy, P., Grivel, J-C., Jolly, G., Brun, N., Barbet, J., and Leserman, L. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J. Immunol., 161: 6059-6067, 1998.
10. van Vugt, M. J., Kleijmeer, M. J., Keler, T., Zeelenberg, I., van Dijk, M. A., Leusen, J. H., Geuze, H. J., and van de Winkel, J. G. J. The FcγRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcRγ-chain. Blood, 94: 808-817, 1999.
11. Strehl, J., Selmayr, M., Kremer, J-P., Hültner, L., Lindhofer, H., and Mocikat, R. Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Int. J. Cancer, 83: 113-120, 1999.
12. Kronenberger, K., Dieckmann, A., Selmayr, M., Strehl, J., Wahl, U., Lindhofer, H., Kraal, G., and Mocikat, R. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. Blood, 99: 1327-1331, 2002.
13. Selmayr, M., Strehl, J., Kremer, J.-P., Kremmer, E., Doenecke, A., Hallek, M., Menzel, H., Thielemans, K., Thierfelder, S., and Mocikat, R. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther., 6: 778-784, 1999.
14. Guyre, P. M., Graziano, R. F., Vance, B. A., Morganelli, P. M., and Fanger, M. W. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol., 143: 1650-1655, 1989.
15. Lengauer, C., Speicher, M. R., Popp, S., Jauch, A., Taniwaki, M., Nagaraja, R., Riethman, H. C., Donis-Keller, H., D'Urso, M., and Schlessinger, D. Chromosomal bar codes produced by multicolor fluorescence in situ hybridization with multiple YAC clones and whole chromosome painting probes. Hum. Mol. Genet., 2: 505-512, 1993.
16. Eils, R., Uhrig, S., Saracoglu, K., Satzler, K., Bolzer, A., Petersen, I., Chassery, J., Ganser, M., and Speicher, M. R. An optimized, fully automated system for fast and accurate identification of chromosomal rearrangements by multiplex-FISH (M-FISH). Cytogenet. Cell Genet., 82: 160-171, 1998.
17. Gatz, S. A., Pohla, H., and Schendel, D. J. A PCR-SSP method to specifically select HLA-A*0201 individuals for immunotherapeutic studies. Tissue Antigens, 55: 532-547, 2000.
18. Espevik, T., and Nissen-Meyer, J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95: 99-105, 1986.
19. Pohla, H., Frankenberger, B., Stadlbauer, B., Oberneder, R., Hofstetter, A., Willimsky, G., Pezzutto, A., Dörken, B., Blankenstein, T., and Schendel, D. J. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant, 25: 83-87, 2000.
20. Buhmann, R., Nolte, A., Emmerich, B., and Hallek, M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood, 93: 1992-2002, 1999.
21. Egeter, O., Mocikat, R., Ghoreschi, K., Dieckmann, A., and Röcken, M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res., 60: 1515-1520, 2000.
22. Provan, D., Bartlett-Pandite, L., Zwicky, C., Neuberg, D., Maddocks, A., Corradini, P., Soiffer, R., Ritz, J., Nadler, L. M., and Gribben, J. G. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 88: 2228-2235, 1996.
23. Korz, C., Pscherer, A., Benner, A., Mertens, D., Schaffner, C., Leupolt, E., Döhner, H., Stilgenbauer, S., and Lichter, P. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood, 99: 4554-4561, 2002.